XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:        
Net product sales $ 103,501 $ 81,691 $ 284,274 $ 241,137
Cost of goods sold 9,946 13,436 26,002 29,215
Gross profit 93,555 68,255 258,272 211,922
Operating expenses:        
Research and development 40,704 52,970 117,352 212,806
Selling, general, and administrative 65,651 47,272 205,031 158,767
Changes in fair value of contingent consideration payable 1,995 567 2,583 (506)
Loss on impairment of assets 0 0 1,134 6,616
Depreciation and amortization 2,228 1,286 5,691 4,031
Total operating expenses 110,578 102,095 331,791 381,714
Loss from operations (17,023) (33,840) (73,519) (169,792)
Other income (expense):        
Interest income 1,471 563 5,407 1,052
Interest expense (12,986) (9,620) (37,322) (26,024)
Other income (expense) 3,833 13,634 (13,007) 22,804
Loss before income tax (24,705) (29,263) (118,441) (171,960)
Income tax benefit (expense) 3,128 (4,023) 700 (8,743)
Net loss attributable to common stockholders $ (21,577) $ (33,286) $ (117,741) $ (180,703)
Net loss attributable to common stockholders per common share - basic (in dollars per share) $ (0.07) $ (0.12) $ (0.40) $ (0.63)
Net loss attributable to common stockholders per common share — diluted (in dollars per share) $ (0.07) $ (0.12) $ (0.40) $ (0.63)
Weighted average common shares outstanding - basic (in shares) 295,759,435 289,223,709 293,314,167 288,841,092
Weighted average common shares outstanding - diluted (in shares) 295,759,435 289,223,709 293,314,167 288,841,092